ERBITUX(Cetuximab) approved for treatment of KRAS wild type metastatic colorectal cancer

Merck Korea announced on October 8 that the Korea Food and Drug Administration has approved Erbitux (cetuximab), a first-in-class and highly active IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), for treatment of patients with KRAS wild type metastatic colorectal cancer (mCRC).

KRAS is a gene that codes for a protein involved in the EGFR pathway. In tumors wit...